Floatz logo

Vasoactive Intestinal Peptide

Acute Respiratory Distress Syndrome

Stony Brook Universityprotein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Acute Respiratory Distress Syndrome cohort.

Asset / SponsorPhaseRating
Protirelin
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 3BB
Vitamin D
Prof. Dr. Jörg Leuppi
Phase 3BB
Flosteron
National Center for Research Resources (NCRR)
Phase 3BB
Dexasone
National Center for Research Resources (NCRR)
Phase 3B
Tocilizumab
National Cancer Institute (NCI)
Phase 2CCC
Molgramostim
Savara Inc.
Phase 1CC
Recombinant Human Keratinocyte Growth Factor-2 For Inhalation
Shanghai Zhongshan Hospital
Early Phase 1C
Oxygen
Evangelismos Hospital
N/AD

Same molecule, other indications

Vasoactive Intestinal Peptide is also rated in:

infectious disease with sepsisDormant
CC
Indicative · Phase 1
47 / 100
View asset →
adult acute respiratory distress syndromeDormant
CC
Indicative · Phase 1
47 / 100
View asset →
migraine without auraDormant
D
Indicative · N/A
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →